Contact Us

FDA Approves Lorbrena as First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer

Imbruvica Plus Novel Agent May Improve Progression-Free Survival in Chronic Lymphocytic Leukemia

How Caregivers Can Become an Active Part of the Cancer Care Team

Strict Cleaning Protocols Induce Limited Traces of Virus That Causes COVID-19 in Cancer Centers